Intravenous prednisolone in chronic bronchial asthma

Area of Science:

• Pulmonology
• Pharmacology
• Clinical Medicine

Background:

• Chronic bronchial asthma significantly impacts pulmonary function.
• Corticosteroids are a cornerstone in asthma management.
• Understanding the pharmacokinetic profile of different corticosteroid formulations is crucial for optimizing treatment.

Purpose of the Study:

• To evaluate the time course of pulmonary function changes following a single intravenous injection of prednisolone phosphate in patients with chronic bronchial asthma.
• To compare the onset and peak effect of intravenous prednisolone phosphate with previously studied oral prednisolone and intravenous hydrocortisone in asthma patients.

Main Methods:

• Ten patients diagnosed with chronic bronchial asthma received a single intravenous injection of 40 mg prednisolone phosphate.
• Pulmonary function tests were conducted over a 30-hour period post-injection to monitor changes.
• Statistical analysis was performed to determine the significance and timing of observed changes.

Main Results:

• Statistically significant improvements in pulmonary function tests were observed as early as one hour after prednisolone phosphate administration.
• The maximum group response was recorded approximately eight hours post-injection.
• The time course of response for intravenous prednisolone phosphate was comparable to that of oral prednisolone, with peak effects occurring around 8-9 hours.
• Intravenous hydrocortisone demonstrated a faster onset of action, with peak effects at five hours.

Conclusions:

• Intravenous prednisolone phosphate provides a rapid and effective improvement in pulmonary function for chronic asthma patients.
• The onset and duration of action of intravenous prednisolone phosphate are similar to oral prednisolone, suggesting a comparable systemic absorption and distribution profile.
• Intravenous hydrocortisone exhibits a quicker peak effect compared to both intravenous and oral prednisolone in this patient population.
• These findings contribute to the understanding of corticosteroid pharmacodynamics in asthma management, guiding formulation selection based on desired onset and duration of action.